Translational Biotechnology Hosted Seminar by Alex Zhavoronkov from Insilico Medicine
|
|
End-to-end AI for Drug DiscoveryAlex Zhavoronkov, PhD Founder and CEO Wednesday, April 20, 2022 |
|||||
|
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine https://insilico.com, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. In this seminar, Dr. Zhavoronkov will present traditional drug discovery and success examples of how AI can improve the process.
|
||||||
